长春西汀治疗冠心病的临床疗效观察  

Clinical observation of coronary heart disease treated with vinpocetine

作　　者：何清林 

机构地区：[1]安徽省广德县中医院老年病科,242200

出　　处：《中国基层医药》2017年第23期3614-3616,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 探讨长春西汀治疗冠心病的临床疗效.方法 选择冠心病患者70例为观察对象,采用随机数字表法分为观察组35例、对照组35例,对照组采用常规治疗,观察组在常规治疗基础上联合长春西汀治疗.观察两组患者治疗前后血清超敏C反应蛋白（hs-CRP）、白细胞介素6（IL-6）的变化,比较两组临床疗效.结果 治疗前两组hs-CRP、IL-6差异均无统计学意义（均P＞0.05）.治疗后,观察组血清hs-CRP、IL-6分别为（4.18 ±0.67）mg/mL、（4.42±0.52） pg/mL,对照组分别为（4.51±0.54） mg/mL、（5.96±0.73） pg/mL,两组差异均有统计学意义（t=2.376、3.218,均P＜0.05）;观察组有效率为94.3％,显著高于对照组的80.0％,两组差异有统计学意义（x^2=4.841,P＜0.05）.结论 在常规治疗基础上,应用长春西汀治疗冠心病,可显著降低血清hs-CRP、IL-6水平,提高临床疗效.Objective To investigate the clinical efficacy of vinpocetine in the treatment of coronary heart disease （CHD）.Methods 70 patients with CHD were selected,and they were randomly divided into observation group（35 cases） and control group （35 cases） according to the digital table.The control group received routine treatment,the observation group received vinpocetine therapy combined with fluoxetine on the basis of routine treatment.The changes of serum high sensitivity C reactive protein（hs-CRP） and interleukin 6（IL-6） were observed before and after treatment in the two groups,and the clinical efficacy of the two groups was compared.Results Before treatment,there were no statistically significant differences in hs-CRP and IL-6 levels between the two groups （all P 〉 0.05）.Mter treatment,the serum hs-CRP and IL-6 levels in the observation group were （4.18 ± 0.67） mg/mL,（4.42 ±0.52） pg/mL,respectively,which in the control group were （4.51 ± 0.54） mg/mL,（5.96 ± 0.73） pg/mL,respectively,there were statistically significant differences between the two groups（t =2.376,3.218,all P 〈 0.05）.The effective rate of the observation group was 94.3%,which was significantly higher than 80.0% of the control group,there was statistically significant difference between the two groups （x^2 =4.841,P 〈 0.05）.Conclusion On the basis of routine treatment,vinpocetine in the treatment of CHD can significantly reduce the serum levels of hs-CRP and IL-6,and improve the clinical efficacy.

关 键 词：冠状动脉疾病 长春西汀 治疗结果 

分 类 号：R541.4[医药卫生—心血管疾病]